摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(5-Chloro-2-hydroxyphenyl)iminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol | 25765-13-3

中文名称
——
中文别名
——
英文名称
4-[(5-Chloro-2-hydroxyphenyl)iminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol
英文别名
——
4-[(5-Chloro-2-hydroxyphenyl)iminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol化学式
CAS
25765-13-3
化学式
C14H13ClN2O3
mdl
——
分子量
292.722
InChiKey
AVOUPCRIYDXPOY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    85.9
  • 氢给体数:
    3
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    4-[(5-Chloro-2-hydroxyphenyl)iminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol二丁基二氯化锡三乙胺 作用下, 以 四氢呋喃 为溶剂, 以85%的产率得到4-[(5-Chloro-2-oxidophenyl)iminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-olate;dibutyltin(2+)
    参考文献:
    名称:
    Bioactive Penta-Coordinated Diorganotin(Iv) Complexes of Pyridoxalimine Schiff Bases
    摘要:
    Diorganotin(IV) complexes of an extended system derived from the condensation of pyridoxal hydrochloride with 2-amino phenol (H2L1), 2-amino-4-methyl phenol (H2L2), 2-amino-4-chloro phenol (H2L3), 2-amino-4-nitro phenol (H2L4), 1-amino-2-naphthol hydrochloride (H2L5) have been synthesized by the reaction of dichlorodiorganotin(IV) in a 1:1 molar ratio with these ligands. Spectral studies (IR, H-1, C-13, Sn-119 NMR) along with physical data evidenced the formation of penta-coordinated species with the ligands acting as tridentate (ONO) with oxygen occupying the axial positions, and nitrogen at one of the equatorial positions. The ligands and their organotin complexes have been evaluated for antimicrobial activity against phytopathogenic fungi Candida albicans and Aspergillus niger at 25 +/- 1 degrees C and bacteria Bacillus subtilis, Escherichia coli, and Staphylococcus aureus at 37 +/- 1 degrees C. The activities of the ligands have been enhanced on complexation and the results indicate that they exhibit significant antimicrobial properties.
    DOI:
    10.1080/10426507.2012.692129
  • 作为产物:
    参考文献:
    名称:
    Bioactive Penta-Coordinated Diorganotin(Iv) Complexes of Pyridoxalimine Schiff Bases
    摘要:
    Diorganotin(IV) complexes of an extended system derived from the condensation of pyridoxal hydrochloride with 2-amino phenol (H2L1), 2-amino-4-methyl phenol (H2L2), 2-amino-4-chloro phenol (H2L3), 2-amino-4-nitro phenol (H2L4), 1-amino-2-naphthol hydrochloride (H2L5) have been synthesized by the reaction of dichlorodiorganotin(IV) in a 1:1 molar ratio with these ligands. Spectral studies (IR, H-1, C-13, Sn-119 NMR) along with physical data evidenced the formation of penta-coordinated species with the ligands acting as tridentate (ONO) with oxygen occupying the axial positions, and nitrogen at one of the equatorial positions. The ligands and their organotin complexes have been evaluated for antimicrobial activity against phytopathogenic fungi Candida albicans and Aspergillus niger at 25 +/- 1 degrees C and bacteria Bacillus subtilis, Escherichia coli, and Staphylococcus aureus at 37 +/- 1 degrees C. The activities of the ligands have been enhanced on complexation and the results indicate that they exhibit significant antimicrobial properties.
    DOI:
    10.1080/10426507.2012.692129
点击查看最新优质反应信息

文献信息

  • Schiff base Sn(IV) complexes as cytotoxic agents: Synthesis, structure, isosteric and bioisosteric replacement
    作者:José M. Galván-Hidalgo、Teresa Ramírez-Apan、Antonio Nieto-Camacho、Simón Hernández-Ortega、Elizabeth Gómez
    DOI:10.1016/j.jorganchem.2017.08.017
    日期:2017.10
    plane and the two oxygen atoms in the equatorial plane. Additionally, the in vitro cytotoxicity tests of the complexes towards six types of human cancerous cell lines U-251 (glioblastoma), K-562 (chronic myelogenous leukemia), HCT-15 (human colorectal), MCF-7 (human breast), MDA-MB-231(human breast) and SKLU-1 (non-small cell lung) showed the superior activity of the organotin complexes compared to the
    据报道,制备和表征了两个系列的有机锡(IV)配合物,每个系列在键合到原子(环己基或双(三甲基)甲硅烷基甲基)上的取代基的性质不同。等规和生物等规方法被用作分子设计的策略。配体是5-羟基甲基-4-[(2-羟基苯基)亚基甲基] -2-甲基吡啶-3-醇,在4位被甲基,卤代(F,Cl),甲氧基,硝基和叔丁基取代;取决于配体的性质,通过多组分策略以合理至高产率进行有机锡(IV)配合物的合成。所有新的配合物均通过IR,MS,X射线测定和NMR(1 H,13 C,119)。配合物的晶体学数据表明,中心周围采用的几何形状在2c的方形字塔形和3b-3d的三角形双字塔形之间变化,烷基在三角平面,两个氧原子在赤道平面。此外,该复合物对六种类型的人类癌细胞系U-251(胶质母细胞瘤),K-562(慢性粒细胞性白血病),HCT-15(人结肠直肠),MCF-7(人乳腺),与相应的顺铂用作阳性对照相比,
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3,3''-双([[1,1''-联苯]-4-基)-[1,1''-联萘]-2,2''-二醇 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-2,2'',3,3''-四氢-6,6''-二-9-菲基-1,1''-螺双[1H-茚]-7,7''-二醇 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (6,6)-苯基-C61己酸甲酯 (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,5R)-3,3a,8,8a-四氢茚并[1,2-d]-1,2,3-氧杂噻唑-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aS,8aR)-2-(吡啶-2-基)-8,8a-二氢-3aH-茚并[1,2-d]恶唑 (3aS,3''aS,8aR,8''aR)-2,2''-环戊二烯双[3a,8a-二氢-8H-茚并[1,2-d]恶唑] (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (3S,3aR)-2-(3-氯-4-氰基苯基)-3-环戊基-3,3a,4,5-四氢-2H-苯并[g]吲唑-7-羧酸 (3R,3’’R,4S,4’’S,11bS,11’’bS)-(+)-4,4’’-二叔丁基-4,4’’,5,5’’-四氢-3,3’’-联-3H-二萘酚[2,1-c:1’’,2’’-e]膦(S)-BINAPINE (3-三苯基甲氨基甲基)吡啶 (3-[(E)-1-氰基-2-乙氧基-2-hydroxyethenyl]-1-氧代-1H-茚-2-甲酰胺) (2′′-甲基氨基-1,1′′-联苯-2-基)甲烷磺酰基铝(II)二聚体 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,4S)-Fmoc-4-三氟甲基吡咯烷-2-羧酸 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环